PLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo
Biomolecules · 2024
DOI: 10.3390/biom14121651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Kate Butcher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK. Hauptthemen laut MEDLINE: Disulfiram, Carcinoma, Non-Small-Cell Lung, Neoplastic Stem Cells, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Lung Foundation.
Abstract (Originalsprache)
Cancer stem cells (CSCs) play a key role in non-small cell lung cancer (NSCLC) chemoresistance and metastasis. In this study, we used two NSCLC cell lines to investigate the regulating effect of hypoxia in the induction and maintenance of CSC traits. Our study demonstrated hypoxia-induced stemness and chemoresistance at levels comparable to those in typical CSC sphere culture. Activation of the NF-κB pathway (by transfection of NF-κB-p65) plays a key role in NSCLC CSCs and chemoresistance. Disulfiram (DS), an anti-alcoholism drug, showed a strong in vitro anti-CSC effect. It blocked cancer cell sphere reformation and clonogenicity, synergistically enhanced the cytotoxicity of four anti-NSCLC drugs (doxorubicin, gemcitabine, oxaliplatin and paclitaxel) and reversed hypoxia-induced resistance. The effect of DS on CSCs is copper-dependent. A very short half-life in the bloodstream is the major limitation for the translation of DS into a cancer treatment. Our team previously developed a poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated DS (DS-PLGA) with a long half-life in the bloodstream. Intra venous injection of DS-PLGA in combination with the oral application of copper gluconate has strong anticancer efficacy in a metastatic NSCLC mouse model. Further study may be able to translate DS-PLGA into cancer applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK.
- Disulfican Ltd., Wolverhampton WV9 5HD, UK.
- School of Biosciences, Division of Natural Sciences, University of Kent, Canterbury CT2 7NZ, UK.
- Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Hospital of North China University of Science and Technology, Tangshan 063000, China.
- Faculty of Health, Medicine and Social Care, Anglia Ruskin University, Cambridge CB1 1PT, UK.
- School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK.
ORCID-Profile: Zaixing Zhang, Mohammad Najlah, Weiguang Wang
Förderung
- British Lung Foundation
Zitieren
APA
Butcher, K., Wang, Z., Kurusamy, S., Zhang, Z., Morris, M. R., Najlah, M., McConville, C., Kannappan, V., & Wang, W. (2024). PLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo. Biomolecules. https://doi.org/10.3390/biom14121651
Vancouver
Butcher K, Wang Z, Kurusamy S, Zhang Z, Morris MR, Najlah M, et al. PLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo. Biomolecules. 2024. doi:10.3390/biom14121651
BibTeX
@article{Butcher2024,
author = {Butcher, Kate and Wang, Zhipeng and Kurusamy, Sathishkumar and Zhang, Zaixing and Morris, Mark R and Najlah, Mohammad and McConville, Christopher and Kannappan, Vinodh and Wang, Weiguang},
title = {PLGA-Nano-Encapsulated Disulfiram Inhibits Cancer Stem Cells and Targets Non-Small Cell Lung Cancer In Vitro and In Vivo},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14121651}
}
EUVIMED